The global breast cancer drug market is poised for significant growth, with a projected valuation of USD 10,733.1 million in 2023. The increasing prevalence of the disease, coupled with the evolution of novel therapies, are key factors expected to drive market expansion. Early detection of breast cancer remains crucial for effective disease management. The overall demand for breast cancer drugs is projected to grow at a compound annual growth rate (CAGR) of 1.1% between 2023 and 2033, reaching approximately USD 12,012.1 million by 2033.
Breast cancer is one of the most common cancers affecting women worldwide, with a substantial impact on public health. The development of innovative therapies, along with advancements in early detection methods, is essential for improving patient outcomes and reducing mortality rates associated with the disease.
Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1246
Breast cancer is the most common cancer to strike women worldwide. The most recent cancer data indicates that 1.7 million cases of breast cancer occur each year. Women in wealthier countries like the United States, the United Kingdom, and Australia are more vulnerable than women in developing countries.
Many factors, including age, heredity, lifestyle, and genetic mutations (abnormal variations), contribute to the development of breast cancer. Scientists are investigating new imaging modalities to evaluate abnormalities in the early phases of the illness and attempting to ascertain the influence of genetic alterations on breast cancer.
Key Takeaways:
- The global breast cancer drug market is projected to reach US$12,012.1 million by 2033, reflecting a rise from US$10,733.1 million in 2023.
- This growth is expected at a moderate compound annual growth rate (CAGR) of 1.1% throughout the forecast period.
- The rising prevalence of breast cancer and the development of novel therapies are key drivers for market expansion.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1246
Competitive Landscape:
- In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.
- In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.
Key Companies Profiled:
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- AstraZeneca
- Novartis International AG
- Achieve Life Science
- Bristol-Myers Squibb
- Eisai Co. Ltd
- AbbVie
- Eli Lilly & Company
- Celgene Corporation
- Merck & Co.
- Amgen Plc.
- Celldex Therapeutics
- Biocon Genzyme Corporation
Key Segments Covered in the Breast Cancer Drug Industry Analysis:
By Drug Class:
- SERM (Selective Estrogen-Receptor Modulators)-based
- Aromatase Inhibitors-based
- Biologic Response Modifiers-based
- Other Hormonal Therapies-based
By Distribution Channel:
- Hospital Pharmacies
- Pharmacies
- Drug Stores
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Explore In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/1246
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
